Osteotropic β-cyclodextrin for local bone regeneration

Xin Ming Liu, Andrew T. Wiswall, John E. Rutledge, Mohammed P. Akhter, Diane M. Cullen, Richard A. Reinhardt, Dong Wang

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

An osteotropic alendronate-β-cyclodextrin conjugate (ALN-β-CD) was developed as a bone-targeting delivery system for improved treatment of skeletal diseases. The conjugate shows very strong binding to hydroxyapatite (HA, main component of the skeleton). Its ability in forming molecular inclusion complex with prostaglandin E1 (PGE1, a potent bone anabolic agent) was confirmed by phase solubility experiments and differential scanning calorimetry (DSC). In a bilateral rat mandible model, ALN-β-CD/PGE1 molecular complex was shown to stimulate strong local bone anabolic reaction. In the control study, ALN-β-CD itself was also found to be bone anabolic. To investigate this finding, other control groups were studied. The histomorphometry data suggest that ALN-β-CD itself could generate more new bone at the injection site than its complex with PGE1. Alendronate (ALN) injection could also cause new bone formation, which locates peripheral to the site of injection. PGE1, saline or ethanol injections do not have anabolic effect. These findings were also confirmed by micro-CT evaluation of mandibular bones. It is clear that the bone anabolic effect of ALN-β-CD is independent of mechanical stimuli of the periosteum or ALN injection alone. Further studies are warranted to understand the working mechanism of ALN-β-CD as a bone anabolic agent.

Original languageEnglish
Pages (from-to)1686-1692
Number of pages7
JournalBiomaterials
Volume29
Issue number11
DOIs
StatePublished - Apr 2008

Fingerprint

Alendronate
Bone Regeneration
Cyclodextrins
Bone
Alprostadil
Anabolic Agents
Bone and Bones
Injections
Periosteum
Differential Scanning Calorimetry
Durapatite
Mandible
Osteogenesis
Skeleton
Solubility
Hydroxyapatite
Ethanol
Rats
Differential scanning calorimetry
Control Groups

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Liu, X. M., Wiswall, A. T., Rutledge, J. E., Akhter, M. P., Cullen, D. M., Reinhardt, R. A., & Wang, D. (2008). Osteotropic β-cyclodextrin for local bone regeneration. Biomaterials, 29(11), 1686-1692. https://doi.org/10.1016/j.biomaterials.2007.12.023

Osteotropic β-cyclodextrin for local bone regeneration. / Liu, Xin Ming; Wiswall, Andrew T.; Rutledge, John E.; Akhter, Mohammed P.; Cullen, Diane M.; Reinhardt, Richard A.; Wang, Dong.

In: Biomaterials, Vol. 29, No. 11, 04.2008, p. 1686-1692.

Research output: Contribution to journalArticle

Liu, XM, Wiswall, AT, Rutledge, JE, Akhter, MP, Cullen, DM, Reinhardt, RA & Wang, D 2008, 'Osteotropic β-cyclodextrin for local bone regeneration', Biomaterials, vol. 29, no. 11, pp. 1686-1692. https://doi.org/10.1016/j.biomaterials.2007.12.023
Liu XM, Wiswall AT, Rutledge JE, Akhter MP, Cullen DM, Reinhardt RA et al. Osteotropic β-cyclodextrin for local bone regeneration. Biomaterials. 2008 Apr;29(11):1686-1692. https://doi.org/10.1016/j.biomaterials.2007.12.023
Liu, Xin Ming ; Wiswall, Andrew T. ; Rutledge, John E. ; Akhter, Mohammed P. ; Cullen, Diane M. ; Reinhardt, Richard A. ; Wang, Dong. / Osteotropic β-cyclodextrin for local bone regeneration. In: Biomaterials. 2008 ; Vol. 29, No. 11. pp. 1686-1692.
@article{b7fcc846c85849048571fc8ab0657ad5,
title = "Osteotropic β-cyclodextrin for local bone regeneration",
abstract = "An osteotropic alendronate-β-cyclodextrin conjugate (ALN-β-CD) was developed as a bone-targeting delivery system for improved treatment of skeletal diseases. The conjugate shows very strong binding to hydroxyapatite (HA, main component of the skeleton). Its ability in forming molecular inclusion complex with prostaglandin E1 (PGE1, a potent bone anabolic agent) was confirmed by phase solubility experiments and differential scanning calorimetry (DSC). In a bilateral rat mandible model, ALN-β-CD/PGE1 molecular complex was shown to stimulate strong local bone anabolic reaction. In the control study, ALN-β-CD itself was also found to be bone anabolic. To investigate this finding, other control groups were studied. The histomorphometry data suggest that ALN-β-CD itself could generate more new bone at the injection site than its complex with PGE1. Alendronate (ALN) injection could also cause new bone formation, which locates peripheral to the site of injection. PGE1, saline or ethanol injections do not have anabolic effect. These findings were also confirmed by micro-CT evaluation of mandibular bones. It is clear that the bone anabolic effect of ALN-β-CD is independent of mechanical stimuli of the periosteum or ALN injection alone. Further studies are warranted to understand the working mechanism of ALN-β-CD as a bone anabolic agent.",
author = "Liu, {Xin Ming} and Wiswall, {Andrew T.} and Rutledge, {John E.} and Akhter, {Mohammed P.} and Cullen, {Diane M.} and Reinhardt, {Richard A.} and Dong Wang",
year = "2008",
month = "4",
doi = "10.1016/j.biomaterials.2007.12.023",
language = "English",
volume = "29",
pages = "1686--1692",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "11",

}

TY - JOUR

T1 - Osteotropic β-cyclodextrin for local bone regeneration

AU - Liu, Xin Ming

AU - Wiswall, Andrew T.

AU - Rutledge, John E.

AU - Akhter, Mohammed P.

AU - Cullen, Diane M.

AU - Reinhardt, Richard A.

AU - Wang, Dong

PY - 2008/4

Y1 - 2008/4

N2 - An osteotropic alendronate-β-cyclodextrin conjugate (ALN-β-CD) was developed as a bone-targeting delivery system for improved treatment of skeletal diseases. The conjugate shows very strong binding to hydroxyapatite (HA, main component of the skeleton). Its ability in forming molecular inclusion complex with prostaglandin E1 (PGE1, a potent bone anabolic agent) was confirmed by phase solubility experiments and differential scanning calorimetry (DSC). In a bilateral rat mandible model, ALN-β-CD/PGE1 molecular complex was shown to stimulate strong local bone anabolic reaction. In the control study, ALN-β-CD itself was also found to be bone anabolic. To investigate this finding, other control groups were studied. The histomorphometry data suggest that ALN-β-CD itself could generate more new bone at the injection site than its complex with PGE1. Alendronate (ALN) injection could also cause new bone formation, which locates peripheral to the site of injection. PGE1, saline or ethanol injections do not have anabolic effect. These findings were also confirmed by micro-CT evaluation of mandibular bones. It is clear that the bone anabolic effect of ALN-β-CD is independent of mechanical stimuli of the periosteum or ALN injection alone. Further studies are warranted to understand the working mechanism of ALN-β-CD as a bone anabolic agent.

AB - An osteotropic alendronate-β-cyclodextrin conjugate (ALN-β-CD) was developed as a bone-targeting delivery system for improved treatment of skeletal diseases. The conjugate shows very strong binding to hydroxyapatite (HA, main component of the skeleton). Its ability in forming molecular inclusion complex with prostaglandin E1 (PGE1, a potent bone anabolic agent) was confirmed by phase solubility experiments and differential scanning calorimetry (DSC). In a bilateral rat mandible model, ALN-β-CD/PGE1 molecular complex was shown to stimulate strong local bone anabolic reaction. In the control study, ALN-β-CD itself was also found to be bone anabolic. To investigate this finding, other control groups were studied. The histomorphometry data suggest that ALN-β-CD itself could generate more new bone at the injection site than its complex with PGE1. Alendronate (ALN) injection could also cause new bone formation, which locates peripheral to the site of injection. PGE1, saline or ethanol injections do not have anabolic effect. These findings were also confirmed by micro-CT evaluation of mandibular bones. It is clear that the bone anabolic effect of ALN-β-CD is independent of mechanical stimuli of the periosteum or ALN injection alone. Further studies are warranted to understand the working mechanism of ALN-β-CD as a bone anabolic agent.

UR - http://www.scopus.com/inward/record.url?scp=38749095190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749095190&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2007.12.023

DO - 10.1016/j.biomaterials.2007.12.023

M3 - Article

VL - 29

SP - 1686

EP - 1692

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 11

ER -